Abstract:EGFR TKI is the standard 1st line therapy for the patients with advanced NSCLC harboring EGFR mutations. While PD-1 checkpoint blockade has become an integral component of disease management for EGFR wild type NSCLC patients at various settings, platinum-based chemotherapy is still the standard of care for EGFR mutated NSCLC pts who progressed after EGFR targeting therapy. Early attempts to combine EGFR TKI with checkpoint blockade had resulted in exacerbated immune related toxicity in the lung. Here we aimed to prospectively evaluate toripalimab, a humanized PD-1 mAb approved for 2nd line treatment of melanoma, in combination with chemotherapy to treat EGFR mutated NSCLC patients failed to EGFR TKI therapies. This is a phase II, multicenter, open-label, single-arm study for pts with EGFR activating mutations who have failed prior EGFR-TKI therapies without T790M mutation or failed osimertinib treatment. Pts were treated with 240mg or 360mg fixed dose toripalimab once every 3 weeks in combination with carboplatin and pemetrexed for up to 6 cycles, followed by toripalimab plus pemetrexed maintenance therapy until disease progression or intolerable toxicity. Primary endpoint was objective response rate as assessed by investigator per RECIST v1.1 once every 6 weeks. Forty pts were enrolled from Apr 25, 2018 to March 22, 2019 with 52.5% female patients and a median age of 57. 57.5% pts harbored EGFR exon19 deletion while 42.5% pts had exon21 L858R mutation. Only 1 pt had T790M mutation who progressed after osimertinib treatment. As of Apr 3 2019, among 31 evaluable pts, 17 partial response and 12 stable disease were observed for a 54.8% ORR (95% CI, 36.0% to 72.7%) and a 93.5% DCR (95% CI, 78.6% to 99.2%). Median PFS was 7.6 months, while median DOR was not reached. Treatment emergent adverse events (TEAE) occurred in 86.5% of the pts, grade 3 or higher events occurred in 51.4% of patients including one death. Most common AE included leukopenia, neutropenia, thrombocytopenia, anemia, nausea, and loss of appetite. Treatment discontinuation due to AE occurred in 10.8% of the pts. Anti-PD-1 mAb, toripalimab in combination with carboplatin and pemetrexed has shown a promising anti-tumor efficacy with a tolerable safety profile for advanced NSCLC patients with EGFR mutated who progressed after EGFR TKI therapies. Pts will be continuously monitored for safety and efficacy readouts (DOR, PFS and OS). A phase III registration study will be initiated in May 2019. (Clinical trial information: NCT03513666)

An Advanced Non-Small Cell Lung Cancer Patient with Epidermal Growth Factor Receptor Sensitizing Mutation Responded to Toripalimab in Combination with Chemotherapy after Resistance to Osimertinib: a Case Report

A Consensus on the Role of Osimertinib in Non-Small Cell Lung Cancer from the AME Lung Cancer Collaborative Group

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

Osimertinib for Egfr T790m Positive Non-Small Cell Lung Cancer-Making It Happen, Turning Good Idea into Great Results

Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired EGFR 19Del/T790M/cis-C797S mutation resistance

Significant Benefits of Osimertinib in Treating Acquired Resistance to First-Generation EGFR-TKIs in Lung Squamous Cell Cancer: A Case Report.

Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

Triple Administration of Osimertinib Followed by Chemotherapy for Advanced Lung Adenocarcinoma: A Case Report

MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies

Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases

Durable Response to Osimertinib in an Advanced Lung Adenocarcinoma Patient with an Uncommon EGFR T854A Mutation: A Case Report

Chemoimmunotherapy Combination: Potential Option for Metastatic NSCLC Patients with EGFR Mutation Resistant to Osimertinib.

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Case Report: Primary Resistance to Osimertinib in Erlotinib-Pretreated Lung Adenocarcinoma with EGFR T790 M Mutation.

Emerging a Novel VOPP1-EGFR Fusion Coexistent with T790M As an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient with EGFR L858R Lung Adenocarcinoma: A Case Report

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports

The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study

Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib